Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study-MedSci.cn

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Song, YQ; Gao, QL; Zhang, HL; Fan, L; Zhou, JF; Zou, DH; Li, W; Yang, HY; Liu, T; Wang, QS; Lv, FF; Guo, HY; Yang, LD; Elstrom, R; Huang, J; Novotny, W; Wei, V; Zhu, J

Zhu, J (corresponding author), Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Lymphoma, Beijing, Peoples R China.

LEUKEMIA, 2020; 34 (2): 533

Abstract

Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of or who are ineligible for autologous s......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

科室

工具

服务